Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime

Ryan K. Shields; Alina Iovleva; Ellen G. Kline; Akito Kawai; Christi L. McElheny; Yohei Doi

doi:10.1093/cid/ciaa355

Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime

Ryan K. Shields
, Alina Iovleva
, Ellen G. Kline
, Akito Kawai
, Christi L. McElheny
, Yohei Doi

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

92 被引用数 (Scopus)

抄録

We report 2 independent patients from whom carbapenem and ceftazidime-avibactam–resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2–amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.

本文言語	英語
ページ（範囲）	2713-2716
ページ数	4
ジャーナル	Clinical Infectious Diseases
巻	71
号	10
DOI	https://doi.org/10.1093/cid/ciaa355
出版ステータス	出版済み - 15-11-2020
外部発表	はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

微生物学（医療）
感染症

文献へのアクセス

10.1093/cid/ciaa355

他のファイルとリンク

フィンガープリント

「Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{80d8864eba054c8db3ae7062d019d7c9,

title = "Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime",

abstract = "We report 2 independent patients from whom carbapenem and ceftazidime-avibactam{\textendash}resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2{\textendash}amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.",

keywords = "Cefepime, Deletion, R2 loop, β-lactamase",

author = "Shields, \{Ryan K.\} and Alina Iovleva and Kline, \{Ellen G.\} and Akito Kawai and McElheny, \{Christi L.\} and Yohei Doi",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2020",

month = nov,

day = "15",

doi = "10.1093/cid/ciaa355",

language = "English",

volume = "71",

pages = "2713--2716",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime

AU - Shields, Ryan K.

AU - Iovleva, Alina

AU - Kline, Ellen G.

AU - Kawai, Akito

AU - McElheny, Christi L.

AU - Doi, Yohei

N1 - Publisher Copyright: © The Author(s) 2020.

PY - 2020/11/15

Y1 - 2020/11/15

N2 - We report 2 independent patients from whom carbapenem and ceftazidime-avibactam–resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2–amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.

AB - We report 2 independent patients from whom carbapenem and ceftazidime-avibactam–resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2–amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.

KW - Cefepime

KW - Deletion

KW - R2 loop

KW - β-lactamase

UR - https://www.scopus.com/pages/publications/85090992686

UR - https://www.scopus.com/pages/publications/85090992686#tab=citedBy

U2 - 10.1093/cid/ciaa355

DO - 10.1093/cid/ciaa355

M3 - Article

C2 - 32236408

AN - SCOPUS:85090992686

SN - 1058-4838

VL - 71

SP - 2713

EP - 2716

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 10

ER -